CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 3,902 enrolled
Drug / intervention
20vPnC +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03760146
NCT03760146Phase 3Completed
CompareCT.gov

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 YEARS OF AGE AND OLDER

Pfizer·interventional·Posted Nov 30, 2018·Updated Dec 2, 2021

In Brief

A Phase 3 clinical trial evaluating 20vPnC, 13vPnC, and 2 other interventions for Pneumococcal Disease. Completed, enrolled 3,902 participants across 68 sites in 2 countries.

Detailed Summary

A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesSweden, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedNov 30, 2018
Enrollment StartDec 12, 2018
Primary CompletionDec 16, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.6 years ago

Interventions

20vPnCbiological

20vPnC

13vPnCbiological

Pneumococcal conjugate vaccine

PPSV23biological

Pneumococcal polysaccharide vaccine

Salineother

Placebo